Arch Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Arch Therapeutics saw a rise in revenue but also experienced a significant increase in net losses during the third quarter of 2024, primarily due to financing expenses.
Arch Therapeutics saw a rise in revenue during the second quarter of 2024, but ongoing losses and reliance on debt financing raise concerns about the company's ability to continue as a going concern.
10-Q: Arch Therapeutics Reports Increased Revenue but Continues to Face Financial Challenges in Q1 2024
Arch Therapeutics saw a significant increase in revenue in the first quarter of 2024 compared to the same period last year, but continues to operate at a loss and faces going concern challenges.